A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.
Standard of care treatment for acute myeloid leukemia is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.
The FDA Oncologic Drugs Advisory Committee voted 12:2 to recommend approval of the drug imetelstat for a myelodysplastic syndrome indication.
The University of Cincinnati Cancer Center has opened the Blood Cancer Healing Center, a facility that aims to advance research, treatment, and wellness for blood cancer patients.
Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.
Richard Edelson began his career at NCI, where he was training to become a cancer immunologist.
FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythemia), in adults with anemia.
Jonathan D. LichtKeith McCraeJonathan Licht and Keith McCrae were selected by The American Society of Hematology to serve as the inaugural editors-in-chief of the newest additions to the Blood Journals portfolio: Blood Neoplasia and Blood Vessels, Thrombosis & Hemostasis, or Blood VTH.
When John Laszlo joined the Acute Leukemia Service at NCI in 1956, the field of oncology was nascent—and the cure for childhood leukemia seemed beyond reach.
Leukemia was mostly a fatal disease when Hagop Kantarjian, a medical student at the American University of Lebanon in Beirut, first came to MD Anderson in 1978.
